ImpediMed Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IPDQF research report →
Companywww.impedimed.com
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics.
- CEO
- Erik Anderson
- IPO
- 2012
- Employees
- 83
- HQ
- Pinkenba, QLD, AU
Price Chart
Valuation
- Market Cap
- $14.27M
- P/E
- -0.50
- P/S
- 0.86
- P/B
- 1.35
- EV/EBITDA
- -0.98
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -5.85%
- Op Margin
- -156.48%
- Net Margin
- -171.25%
- ROE
- -165.13%
- ROIC
- -68.21%
Growth & Income
- Revenue
- $12.72M · 26.57%
- Net Income
- $-23,237,000 · -17.42%
- EPS
- $-0.01 · -17.35%
- Op Income
- $-24,231,000
- FCF YoY
- 25.17%
Performance & Tape
- 52W High
- $0.05
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 1.21
- Avg Volume
- 3.51K
Get TickerSpark's AI analysis on IPDQF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IPDQF Coverage
We haven't published any research on IPDQF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IPDQF Report →